证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-5.9%，算上全部成本后，公司产品或 服务的附加值不高。从历史年报数据统计来看，公司上市以来中位数ROIC为9.45%，投资回报也较好， 其中最惨年份2024年的ROIC为-0.46%，投资回报极差。公司历史上的财报相对一般(注：公司上市时间 不满10年，上市时间越长财务均分参考意义越大。)，公司上市来已有年报3份，亏损年份1次，需要仔 细研究下有无特殊原因。商业模式：公司业绩主要依靠资本开支驱动，还需重点关注公司资本开支项目 是否划算以及资本支出是否刚性面临资金压力。需要仔细研究这类驱动力背后的实际情况。 财报体检工具显示：建议关注公司现金流状况(货币资金/总资产仅为4.56%、货币资金/流动负债仅为 35.76%、近3年经营性现金流均值/流动负债仅为2.09%)建议关注公司债务状况(有息资产负债率已达 41.79%、有息负债总额/近3年经营性现金流均值已达156.56%)建议关注财务费用状况(财务费用/近3年经 营性现金流均值已达287.78%)建议关注公司应收账款状况(年报归母净利润为负) 据证券之星公开数据整理，近期共同药业(300966)发布 ...

Group 1 - Xianju Pharmaceutical Co., Ltd. has experienced a decline in stock price for seven consecutive trading days, with a cumulative drop of -5.94% [1] - The company, founded in 1972, aims to become one of the top ten steroid drug suppliers globally and focuses on the steroid hormone sector [1] - In the second quarter of this year, Xianju Pharmaceutical was added to the top ten shareholders of the Xinchuan He Feng three-year holding mixed fund, which has achieved a year-to-date return of 20.55% [1] Group 2 - Yang Shijin and Zhu Kefei are the current fund managers of the Xinchuan He Feng three-year holding mixed fund [4] - Zhu Kefei has been managing the fund since July 2, 2025, and has a tenure of 36 days with a return of 8.40% [3] - Xingsheng Global Fund Management Co., Ltd. was established in September 2003 and is co-owned by Xinyi Securities Co., Ltd. and Global Life Insurance International Company [3]